Question for written answer E-006593/2020
to the Commission
Rule 138
Joëlle Mélin (ID), **Silvia Sardone** (ID), **Stefania Zambelli** (ID)

Subject: Inadequacy of the regulation on medicinal products for paediatric use

In 2016, an oral question and a motion for a resolution on the Regulation on medicinal products for paediatric use (2016/2902 (RSP)) — the Paediatric Regulation — was tabled by the groups in Parliament for the Commission.

It had become clear that while the Paediatric Regulation had helped to improve the overall situation and brought tangible benefits for a range of children's diseases, too little progress had been made in a number of areas, in particular paediatric oncology and neonatology.

The aim of the resolution was therefore to ask the Commission to present a report identifying barriers to innovation in medicines targeting the paediatric population, but also to examine the possibility of amending the Paediatric Regulation.

Four years on and the Commission has still not reacted.

In the context of the launch of the Special Committee on Combating Cancer, whose mission is to tackle all aspects of the disease, including child cancer, can the Commission explain the follow-up it intends to take on the motion for a resolution tabled four years ago?